{"pmid":32423954,"title":"Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.","text":["Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.","A life-threatening, emerging respiratory disease called Coronavirus Disease 2019 (COVID-19) 26 originated in the city of Wuhan in China's Hubei province in December, 2019 and has been classified as 27 an international pandemic by the World Health Organization.....","Antimicrob Agents Chemother","Gordy, James T","Mazumdar, Kaushiki","Dutta, Noton K","32423954"],"abstract":["A life-threatening, emerging respiratory disease called Coronavirus Disease 2019 (COVID-19) 26 originated in the city of Wuhan in China's Hubei province in December, 2019 and has been classified as 27 an international pandemic by the World Health Organization....."],"journal":"Antimicrob Agents Chemother","authors":["Gordy, James T","Mazumdar, Kaushiki","Dutta, Noton K"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423954","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1128/AAC.00857-20","locations":["Wuhan","China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667252837706366977,"score":9.490897,"similar":[{"pmid":32251634,"pmcid":"PMC7194560","title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","text":["Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.","Life Sci","Kandeel, Mahmoud","Al-Nazawi, Mohammed","32251634"],"abstract":["AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment."],"journal":"Life Sci","authors":["Kandeel, Mahmoud","Al-Nazawi, Mohammed"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251634","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.lfs.2020.117627","keywords":["2019-novel coronavirus","covid-19, 2019-ncov","main protease","molecular modeling","wuhan coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ribavirin","Vitamin B 12","Telbivudine","Niacinamide"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490946977792,"score":116.01083},{"pmid":32462970,"title":"Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","text":["Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19.","SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge.","J Biomol Struct Dyn","Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra","32462970"],"abstract":["SARS-CoV-2 is causative agent of COVID 19, which is responsible for severe social and economic disruption globally. Lack of vaccine or antiviral drug with clinical efficacy suggested that drug repurposing approach may provide a quick therapeutic solution to COVID19. Nonstructural Protein-15 (NSP15) encodes for an uridylate-specific endoribonuclease (EndoU) enzyme, essential for virus life cycle and an attractive target for drug development. We have performed in silico based virtual screening of FDA approved compounds targeting EndoU in search of COVID19 drugs from commercially available approved molecules. Two drugs Glisoxepide and Idarubicin used for treatment for diabetes and leukemia respectively were selected as stronger binder of EndoU. Both the drugs bound to the active site of the viral endonuclease by forming attractive intermolecular interactions with catalytically essential amino acid residues, His235, His250 and Lys290. Molecular dynamics simulation studies showed stable conformation dynamics upon drugs binding to endoU. The binding free energies for Glisoxepide and Idarubicin were calculated to be -141 +/- 11 and -136 +/- 16 kJ/mol respectively. The IC50 were predicted to be 9.2microM and 30microM for Glisoxepide and Idarubicin respectively. Comparative structural analysis showed the stronger binding of EndoU to Glisoxepide and Idarubicin than uridine monophosphate (UMP). Surface area calculations showed buried are of 361.8A(2) by Glisoxepide which is almost double of the area occupied by UMP suggesting stronger binding of the drug than the ribonucleotide. However, further studies on these drugs for evaluation of their clinical efficacy and dose formulations may be required, which may provide a quick therapeutic option to treat COVID-19.Abbreviation: COVID-19: Coronavirus Disease 2019; PCA: Principal Component Analysis; MD: Molecular Dynamics; MM/PBSA: Molecular Mechanics Poisson-Boltzmann Surface Area; nCoV: Novel Coronavirus; PME: Particle-Mesh Ewald; RMSD: Root Mean Square Deviations; RMSF: Root Mean Square Fluctuations; SARS-CoV-2: Severe Acute Respiratory Syndrome-Coronavirus-2; SASA: Solvent Accessible Surface Area; SPC: Simple Point Charge."],"journal":"J Biomol Struct Dyn","authors":["Chandra, Anshuman","Gurjar, Vaishali","Qamar, Imteyaz","Singh, Nagendra"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462970","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1775127","keywords":["binding affinity","drug repurposing","endonuclease","ic50","molecular dynamic simulation","sars-cov-2"],"e_drugs":["Amino Acids, Essential","Uridine Monophosphate","Ribonucleotides","glisoxepide","Idarubicin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521291567104,"score":102.339874},{"pmid":32320825,"pmcid":"PMC7166307","title":"Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","text":["Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.","Infect Genet Evol","Abd El-Aziz, Tarek Mohamed","Stockand, James D","32320825"],"abstract":["Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year."],"journal":"Infect Genet Evol","authors":["Abd El-Aziz, Tarek Mohamed","Stockand, James D"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320825","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.meegid.2020.104327","keywords":["covid-19","coronavirus","pathogenesis","sars-cov-2","severe acute respiratory syndrome","therapy","vaccines"],"locations":["Wuhan","Hubei","China","Japan","China"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493599875072,"score":94.23243},{"pmid":32366720,"title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.","text":["Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.","Drug repositioning is the only feasible option to address the COVID-19 global challenge immediately. We screened a panel of 48 FDA-approved drugs against SARS-CoV-2 which were pre-selected by an assay of SARS-CoV and identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low micromolar IC50s and in particular, two FDA-approved drugs - niclosamide and ciclesonide - were notable in some respects.","Antimicrob Agents Chemother","Jeon, Sangeun","Ko, Meehyun","Lee, Jihye","Choi, Inhee","Byun, Soo Young","Park, Soonju","Shum, David","Kim, Seungtaek","32366720"],"abstract":["Drug repositioning is the only feasible option to address the COVID-19 global challenge immediately. We screened a panel of 48 FDA-approved drugs against SARS-CoV-2 which were pre-selected by an assay of SARS-CoV and identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low micromolar IC50s and in particular, two FDA-approved drugs - niclosamide and ciclesonide - were notable in some respects."],"journal":"Antimicrob Agents Chemother","authors":["Jeon, Sangeun","Ko, Meehyun","Lee, Jihye","Choi, Inhee","Byun, Soo Young","Park, Soonju","Shum, David","Kim, Seungtaek"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366720","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/AAC.00819-20","e_drugs":["ciclesonide","Niclosamide"],"topics":["Treatment"],"weight":1,"_version_":1666138496207683584,"score":93.216805},{"pmid":32173188,"pmcid":"PMC7118614","title":"[Recommendations on the clinical management of the COVID-19 infection by the <<new coronavirus>> SARS-CoV2. Spanish Paediatric Association working group].","text":["[Recommendations on the clinical management of the COVID-19 infection by the <<new coronavirus>> SARS-CoV2. Spanish Paediatric Association working group].","On 31 December 2019, the Wuhan Municipal Committee of Health and Healthcare (Hubei Province, China) reported that there were 27 cases of pneumonia of unknown origin with symptoms starting on the 8 December. There were 7 serious cases with common exposure in market with shellfish, fish, and live animals, in the city of Wuhan. On 7 January 2020, the Chinese authorities identified that the agent causing the outbreak was a new type of virus of the Coronaviridae family, temporarily called <<new coronavirus>>, 2019-nCoV. On January 30th, 2020, the World Health Organisation (WHO) declared the outbreak an International Emergency. On 11 February 2020 the WHO assigned it the name of SARS-CoV2 and COVID-19 (SARS-CoV2 and COVID-19). The Ministry of Health summoned the Specialties Societies to prepare a clinical protocol for the management of COVID-19. The Spanish Paediatric Association appointed a Working Group of the Societies of Paediatric Infectious Diseases and Paediatric Intensive Care to prepare the present recommendations with the evidence available at the time of preparing them.","An Pediatr (Barc)","Calvo, Cristina","Garcia Lopez-Hortelano, Milagros","de Carlos Vicente, Juan Carlos","Vazquez Martinez, Jose Luis","32173188"],"abstract":["On 31 December 2019, the Wuhan Municipal Committee of Health and Healthcare (Hubei Province, China) reported that there were 27 cases of pneumonia of unknown origin with symptoms starting on the 8 December. There were 7 serious cases with common exposure in market with shellfish, fish, and live animals, in the city of Wuhan. On 7 January 2020, the Chinese authorities identified that the agent causing the outbreak was a new type of virus of the Coronaviridae family, temporarily called <<new coronavirus>>, 2019-nCoV. On January 30th, 2020, the World Health Organisation (WHO) declared the outbreak an International Emergency. On 11 February 2020 the WHO assigned it the name of SARS-CoV2 and COVID-19 (SARS-CoV2 and COVID-19). The Ministry of Health summoned the Specialties Societies to prepare a clinical protocol for the management of COVID-19. The Spanish Paediatric Association appointed a Working Group of the Societies of Paediatric Infectious Diseases and Paediatric Intensive Care to prepare the present recommendations with the evidence available at the time of preparing them."],"journal":"An Pediatr (Barc)","authors":["Calvo, Cristina","Garcia Lopez-Hortelano, Milagros","de Carlos Vicente, Juan Carlos","Vazquez Martinez, Jose Luis"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173188","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.anpedi.2020.02.001","keywords":["2019-ncov","covid-19","children","coronavirus","infeccion respiratoria","ninos","respiratory infection","sars-cov2"],"locations":["China","Wuhan","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138492597436418,"score":93.06112}]}